NeuroRx is leading US development of RLF-100 (Aviptadil) on behalf of Relief Therapeutics’ (RLF) WILMINGTON, DE and RADNOR, PA / ACCESSWIRE / March 25, 2020 / NeuroRx, a clinical stage biopharma company focused on development of CNS drugs, today announced an expansion of scope to include the co-development of a potentially lifesaving drug for COVID-related […]

NEW YORK, Feb. 10, 2020 /PRNewswire/ — NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am.  The company’s CEO, Dr. Jonathan Javitt will be presenting an overview of recent results obtained with NRX-101, the only clinical stage drug in current development for suicidal bipolar depression.  NRX-101 has been […]

Company to attend upcoming JP Morgan Healthcare Conference WILMINGTON, Del., Jan. 8, 2020 /PRNewswire/ — NeuroRx, Inc announced that it has received a notice of patent allowance covering the Composition of Matter for its drug NRX-101, which targets suicidal bipolar depression, an unmet medical need that results in the death of more than 25,000 Americans each […]

Conducting Phase 3 trial for NRX-101, an FDA-designated Breakthrough Therapy for Suicidal Bipolar Depression WILMINGTON, DE / ACCESSWIRE / November 12, 2019 / NeuroRx, Inc. (NeuroRx) a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it will participate in the Solebury Trout KOL Day for analysts and […]

WILMINGTON, Del., Oct. 23, 2019 /PRNewswire/ — NeuroRx, Inc (NeuroRx) announced that it has signed an agreement with GEM Global Yield LLC SCS (“GEM“), the New York based private alternative investment group to provide the NeuroRx with up to HK$ 750 million over a 30 month term following a public listing of NeuroRx’s common stock. NeuroRx […]

WILLMINGTON, Del., Sept. 9, 2019 /PRNewswire/ — NeuroRX, a phase 3 biopharma company focused on development of NRX-101, an FDA-designated Breakthrough Therapy for Severe Bipolar Depression with Acute Suicidal Ideation, will present a corporate overview at today’s H.C. Wainwright 21st Annual Global Investment Conference in New York. In addition to the presentation by Dr. Jonathan […]

Pivotal study will test novel, oral antidepressant in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation & Behavior following initial stabilization with ketamine PHILADELPHIA, July 9, 2019 /PRNewswire/ — NeuroRx, Inc., a clinical stage biopharma company focused on development of drugs targeting depression and suicidality, announced today that it has initiated a pivotal Phase […]

First drug targeting suicidal bipolar depression, awarded FDA Breakthrough Therapy Designation PHILADELPHIA, June 3, 2019 /PRNewswire/ — NeuroRX, a clinical-stage biopharma company developing the first oral therapy for Severe Bipolar Depression with Acute Suicidal Ideation or Behavior, will present phase 2 efficacy results from its trial of NRX-101, at today’s BIO International Convention in Philadelphiia, PA. […]

Findings suggest potential efficacy for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine. PHILADELPHIA, May 30, 2019 /PRNewswire/ — NeuroRx, a clinical stage biopharma company focused on development of drugs to target suicidal depression and PTSD, announced statistically significant final results from its Phase 2 STABIL-B study […]

Findings suggest potential for NRX-101 in maintaining remission from Severe Bipolar Depression with Acute Suicidal Ideation following initial stabilization with ketamine WILMINGTON, Del.–(BUSINESS WIRE)– NeuroRx, a clinical stage biopharma company focused on the development of Rapid Acting Antidepressants (RAADs) that target the brain’s NMDA receptor, announced results from its Phase 2 STABIL-B study of NRX-101 […]